Clinical Trial Update: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as salvage therapy for transplant-eligible patients with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma Not Otherwise Specified
• Cutaneous Diffuse Large B-cell Lymphoma Leg Type
• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Transformed From Marginal Zone Lymphoma
• Follicular Lymphoma Transformed to Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• T-cell Histiocyte-rich Large B-cell Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Lenalidomide (lenalidomide)
• tafasitamab (tafasitamab)

Snippet

Sponsor: David Bond, MD | Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Status: RECRUITING